Precipio, Inc., formerly Transgenomic, Inc., incorporated on March 6, 1997, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR).The Company’s laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. The Company’s laboratory employs a range of genomic testing service technologies, including its MX-ICP technology. ICE COLD-PCR is a sensitivity platform technology, which enables adoption of personalized, precision medicine in cancer and other diseases. MX-ICP enables detection of multiple known and unknown mutations from sample types, including tissue biopsies, blood, urine, saliva, cell-free deoxyribonucleic acid (cfDNA) and circulating tumor cells (CTCs) at levels over 1,000-fold higher than standard DNA sequencing techniques.
|Bank Name||Precipio, Inc.|
|Industry||Biotechnology: Laboratory Analytical Instruments|
|CEO||Mr. Ilan Danieli|